Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis-Reference-Cited by-同舟云学术

Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis

Published:2021-01-01 Issue:1 Volume:26 Page:186-198
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Edahiro Taro¹,Kawase Takakazu¹,Nagoshi Hisao¹,Fujino Keita¹,Toishigawa Kayo¹^ORCID,Miyama Takahiko¹,Mino Tatsuji¹,Yoshida Tetsumi¹,Morioka Takehiko¹,Hirata Yuji¹,Noma Mitsunori²,Fujii Teruhisa²,Nishizawa Masatoshi³,Fukushima Noriyasu¹^ORCID,Ichinohe Tatsuo¹³

Affiliation:

1. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan

2. Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan

3. Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan

Funder

Japan Agency for Medical Research and Development

Hiroshima University

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.1881228

Reference39 articles.

1. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

2. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis